Eighty per cent more patients in 10 years of UK molecular radiotherapy: Internal Dosimetry Users Group survey results from 2007 to 2017

The Internal Dosimetry Users Group has surveyed UK molecular radiotherapy (MRT) activity for cancer treatment in the UK. Data are presented here spanning 10 years of MRT activity across 31 UK centres, one from Northern Ireland, one from Wales, two from Scotland and 27 from England. Results were compiled from a survey of 2007 activity by the British Institute of Radiology Molecular Radiotherapy Working Party 1, subsequent matched surveys by Internal Dosimetry Users Group of data from 2011, 2012, 2013, 2014 and 2015 which have previously been presented 2,3 and new data from 2016 and 2017. The 2011 and 2012 surveys were carried out online using a dedicated webpage and subsequent surveys were distributed by email, all being publicized widely within the nuclear medicine and medical physics communities. Centres were asked a range of questions about MRT but presented here are data on the number of patients and treatments for each therapy type, activity regimens and trial participation. Treatments identified were Na131I radioiodine (RAI) for thyroid cancer, 131I-metaiodobenzylguanidine (131I-mIBG) and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs), 89Sr-chloride, 153Sm-EDTMP and 223Ra-chloride (Xofigo; Bayer, Leverkusen, Germany) for bone metastases, MRT for haematological malignancies and selective internal radionuclide therapy (SIRT) for liver metastases.